← Leaderboards
Frank Lin
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorDna DamageRadioligandFolh1 GeneSafetyNeuroendocrine TumorsPharmaceutical PreparationsFutureUptakeParagangliomaRadioisotopesMalignant NeoplasmsClinical TrialsCohortDoseLiteraturePhase 2 StudyPhase I/Ii Clinical TrialProgression-Free SurvivalsLutetiumBiodistributionEnrollmentDna Single Strand BreakMaximum Tolerated Dose
Grant awards (40)
Pb212 VMT alpha NET in treatment and re-treatment of SSTR+ tumors$301,170
ZIA · FY2025 · CA · contact PI
Improving PSMA-based radioligand therapy via combination radioligand therapy$150,585
ZIA · FY2025 · CA · contact PI
Phase 2 study of Lu-177-DOTATATE in inoperable paraganglioma - pheochromocytoa$150,585
ZIA · FY2025 · CA · contact PI
Phase 1-2 study of Lu177-DOTATATE and olaparib in neuroendocrine tumors$75,293
ZIA · FY2025 · CA · contact PI
Protection of Salivary Gland in PSMA-targeted radioligand therapy$75,293
ZIA · FY2025 · CA · contact PI
Pb212 VMT alpha NET in treatment and re-treatment of SSTR+ tumors$340,457
ZIA · FY2024 · CA · contact PI
Phase 2 study of Lu-177-DOTATATE in inoperable paraganglioma - pheochromocytoa$170,228
ZIA · FY2024 · CA · contact PI
Improving PSMA-based radioligand therapy via combination radioligand therapy$170,228
ZIA · FY2024 · CA · contact PI
Phase 1-2 study of Lu177-DOTATATE and olaparib in neuroendocrine tumors$85,115
ZIA · FY2024 · CA · contact PI
Protection of Salivary Gland in PSMA-targeted radioligand therapy$85,115
ZIA · FY2024 · CA · contact PI
Pb212 VMT alpha NET in treatment and re-treatment of SSTR+ tumors$337,122
ZIA · FY2023 · CA · contact PI
Phase 2 study of Lu-177-DOTATATE in inoperable paraganglioma - pheochromocytoa$168,560
ZIA · FY2023 · CA · contact PI
Improving PSMA-based radioligand therapy via combination radioligand therapy$168,560
ZIA · FY2023 · CA · contact PI
Phase 1-2 study of Lu177-DOTATATE and olaparib in neuroendocrine tumors$84,281
ZIA · FY2023 · CA · contact PI
Protection of Salivary Gland in PSMA-targeted radioligand therapy$84,281
ZIA · FY2023 · CA · contact PI
Protection of Salivary Gland in PSMA-targeted radioligand therapy$343,726
ZIA · FY2022 · CA · contact PI
Phase 2 study of Lu-177-DOTATATE in inoperable paraganglioma - pheochromocytoa$171,864
ZIA · FY2022 · CA · contact PI
Improving PSMA-based radioligand therapy via combination radioligand therapy$171,864
ZIA · FY2022 · CA · contact PI
Phase 1-2 study of Lu177-DOTATATE and olaparib in neuroendocrine tumors$85,931
ZIA · FY2022 · CA · contact PI
Th227-mesothelin and Zr89-mesothelin antibody conjugate in mesothelin tumors$85,931
ZIA · FY2022 · CA · contact PI
Protection of Salivary Gland in PSMA-targeted radioligand therapy$300,644
ZIA · FY2021 · CA · contact PI
Phase 2 study of Lu-177-DOTATATE in inoperable paraganglioma - pheochromocytoa$150,323
ZIA · FY2021 · CA · contact PI
Improving PSMA-based radioligand therapy via combination radioligand therapy$150,323
ZIA · FY2021 · CA · contact PI
Phase 1-2 study of Lu177-DOTATATE and olaparib in neuroendocrine tumors$75,161
ZIA · FY2021 · CA · contact PI
Th227-mesothelin and Zr89-mesothelin antibody conjugate in mesothelin tumors$75,161
ZIA · FY2021 · CA · contact PI
Protection of Salivary Gland in PSMA-targeted radioligand therapy$311,290
ZIA · FY2020 · CA · contact PI
Improving PSMA-based radioligand therapy via combination radioligand therapy$155,645
ZIA · FY2020 · CA · contact PI
Phase 2 study of Lu-177-DOTATATE in inoperable paraganglioma - pheochromocytoa$155,645
ZIA · FY2020 · CA · contact PI
Phase 1-2 study of Lu177-DOTATATE and olaparib in neuroendocrine tumors$77,823
ZIA · FY2020 · CA · contact PI
Th227-mesothelin and Zr89-mesothelin antibody conjugate in mesothelin tumors$77,823
ZIA · FY2020 · CA · contact PI
Protection of Salivary Gland in PSMA-targeted radioligand therapy$304,086
ZIA · FY2019 · CA · contact PI
Phase 2 study of Lu-177-DOTATATE in inoperable paraganglioma - pheochromocytoa$152,042
ZIA · FY2019 · CA · contact PI
Improving PSMA-based radioligand therapy via combination radioligand therapy$152,042
ZIA · FY2019 · CA · contact PI
Phase 1-2 study of Lu177-DOTATATE and olaparib in neuroendocrine tumors$76,022
ZIA · FY2019 · CA · contact PI
Th227-mesothelin and Zr89-mesothelin antibody conjugate in mesothelin tumors$76,022
ZIA · FY2019 · CA · contact PI
Phase 2 study of Lu-177-DOTATATE in inoperable paraganglioma pheochromocytoa$410,622
ZIA · FY2018 · CA · contact PI
Protection of Salivary Gland in PSMA-targeted radioligand therapy$136,874
ZIA · FY2018 · CA · contact PI
Phase 12 study of Lu177-DOTATATE and olaparib in neuroendocrine tumors$68,437
ZIA · FY2018 · CA · contact PI
Th227-mesothelin antibody conjugate in mesothelioma$68,437
ZIA · FY2018 · CA · contact PI
Phase 2 study of Lu-177-DOTATATE in inoperable paraganglioma pheochromocytoa$414,789
ZIA · FY2017 · CA · contact PI